Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485055 | 0.94 | HRH3 (0.73) | HRH3MEN1KMT2A | |
| SCHEMBL2491157 | 0.93 | HRH3 (0.66) | HRH3MEN1KMT2A | |
| SCHEMBL2488597 | 0.92 | HRH3 (0.76) | HRH3MEN1KMT2A | |
| SCHEMBL2491246 | 0.88 | HRH3 (0.70) | HRH3MEN1KMT2A | |
| SCHEMBL2486143 | 0.88 | HRH3 (0.70) | HRH3MEN1KMT2A | |
| SCHEMBL2489051 | 0.88 | HRH3 (0.70) | HRH3MEN1KMT2A | |
| SCHEMBL2487947 | 0.88 | HRH3 (0.73) | HRH3MEN1KMT2A | |
| SCHEMBL2485822 | 0.87 | HRH3 (0.72) | HRH3MEN1KMT2A | |
| SCHEMBL2488407 | 0.87 | HRH3 (0.66) | HRH3MEN1KMT2A | |
| SCHEMBL2443281 | 0.87 | HRH3 (0.88) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379505-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | Designmedix, Inc. (US) | 2011-10-26 | — | — | EP | claimed |
| WO-2010065932-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | DESIGNMEDIX, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| US-8658648-B2 | Modified chloroquines with single ring moiety or fused ring moiety | DESIGNMEDIX, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2379505-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | Designmedix, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110251210-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | PORTLAND STATE UNIVERSITY (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2010065932-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | DESIGNMEDIX, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251210-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | QARS1, MAVS, QDPR | HRH3 831/4885MEN1 3619/4885KMT2A 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.